ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 214 filers reported holding ROYALTY PHARMA PLC in Q1 2021. The put-call ratio across all filers is 1.03 and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,786 | -76.8% | 58,095 | -72.8% | 0.17% | -78.4% |
| Q1 2023 | $7,690 | -11.5% | 213,430 | -3.0% | 0.78% | -15.9% |
| Q4 2022 | $8,692 | -99.9% | 219,940 | -3.6% | 0.93% | -10.2% |
| Q3 2022 | $9,171,000 | -5.8% | 228,250 | -1.4% | 1.04% | +3.8% |
| Q2 2022 | $9,734,000 | +8.8% | 231,545 | +0.8% | 1.00% | +41.5% |
| Q1 2022 | $8,949,000 | -1.5% | 229,685 | +0.8% | 0.71% | +7.3% |
| Q4 2021 | $9,083,000 | +8.7% | 227,935 | -1.5% | 0.66% | +6.8% |
| Q3 2021 | $8,359,000 | +17.9% | 231,305 | +33.7% | 0.62% | +26.0% |
| Q2 2021 | $7,092,000 | -5.7% | 173,025 | +0.3% | 0.49% | -15.4% |
| Q1 2021 | $7,523,000 | -13.1% | 172,475 | -0.3% | 0.58% | -18.1% |
| Q4 2020 | $8,657,000 | +33.4% | 172,975 | +12.1% | 0.71% | +12.8% |
| Q3 2020 | $6,489,000 | – | 154,250 | – | 0.63% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |